NFL Biosciences Restructures Scientific Committee for NFL-101 Advancement

On May 12, 2025, NFL Biosciences, a biopharmaceutical firm from Montpellier, France, announced it has restructured its Scientific Committee. This enhancement aims to support the development of NFL-101, a botanical smoking cessation therapy, expected to enter Phase 3 clinical trials. NFL-101 is recognized for its novel formulation that requires just two administrations and boasts better tolerability and efficacy than varenicline in reducing cravings.

Three renowned experts in addiction research and a leading immunologist join NFL Biosciences' committee. Harvard's Prof. Scott E. Lukas, expert in nicotine addiction, continues his collaboration. Prof. Bernard Le Foll from the University of Toronto adds his expertise in tobacco addiction. From the University of Tasmania, Prof. Stuart G. Ferguson contributes with his knowledge in smoking cessation strategies. Finally, Paris-based Prof. Eric Tartour, an immunology specialist, strengthens the team.

This strategic move highlights the company’s dedication to advancing NFL-101 towards regulatory approval, aiming for a significant breakthrough in smoking addiction treatment.